Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
ALC.6 (A041501), A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL, has been centrally activated.
About the trial
All participants at our member sites will be required to attest to the completion of this one-time training requirement by April 30, 2019.
Dr Lacey Pitre is an Oncologist and CCTG researcher at the Northeast Cancer Centre in Sudbury, she spoke at a press conference earlier this month to help kick off the Canadian Cancer Society's Daffodil Campaign in Northern Ontario.
The MA36 study team would like to thank everyone who helped them reach the 34 patient accrual goal for this important study.
MA36 is a Randomised, Double-Blind, Parallel group, Placebo-Controlled Multicenter Phase III Study to Assess the Efficacy and Safety of Olaparib versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy.
Dr. Yee Ung will be stepping down as the CCTG radiation oncology co-chair of the thoracic disease site committee as of April 2019, and we are calling for applicants to this position.
The applicant should be a thoracic oncology staff radiation oncologist practicing in a CCTG member Institution in Canada, with international or national leadership experience in clinical trials.
Please be aware that there have been training updates for the Good Clinical Practice Revision 2 implementation. As background, GCP Revision 2 was approved by the ICH regulatory committee November 6, 2016 and Health Canada will implement Revision 2 April 1st, 2019. CCTG communicated a 3 year expiry for GCP certification in spring 2018.
We are fast approaching the CCTG Spring Meeting 2019 #CCTG2019 and here is an update on what you need to know about deadlines and due dates.
